Stockscreener 앱 받기
6.30
4.69%
-0.31
시간 외 거래:
6.31
0.010
+0.16%
전일 마감가:
$6.61
열려 있는:
$6.6
하루 거래량:
99,047
Relative Volume:
0.84
시가총액:
$33.40M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-4.20
EPS:
-1.5
순현금흐름:
$-171.05M
1주 성능:
-4.55%
1개월 성능:
-22.94%
6개월 성능:
-66.40%
1년 성능:
-82.74%
1일 변동 폭
$6.22
$6.60
1주일 범위
$6.22
$7.05
52주 변동 폭
$6.22
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
6.30 | 33.40M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Revenues Working Against Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Share Price Following 25% Dive - simplywall.st
Is Mersana Therapeutics Inc. still worth holding after the dipAI-Based Reversal Point Prediction Signal - Newser
Will Mersana Therapeutics Inc. outperform the marketPattern Recognition Tool for ROI Investors - Newser
Will Mersana Therapeutics Inc. stock go up soonBuy and Hold Strategy for Capital Safety - Newser
Mersana Therapeutics Inc.’s volatility index tracking explainedFree Entry Alert Based on Volume Spikes - Newser
Competitive Positioning of Mersana Therapeutics Inc.: Is It Leading or LaggingGrowth Watchlist for Long Term Positioning - Newser
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN Stock News - GuruFocus
Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewswire
Leading Cancer ADC Developer Mersana Therapeutics Reveals Q2 2025 Earnings Date: Pipeline Updates Expected - Stock Titan
Mersana Therapeutics (NASDAQ:MRSN) Cut to “Strong Sell” at Wall Street Zen - Defense World
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsTrading Volume Anomaly Summary and Insight - Newser
What are analysts’ price targets for Mersana Therapeutics Inc. in the next 12 monthsAchieve breakthrough gains with expert advice - Jammu Links News
Mersana Therapeutics Inc. Recovers — But Is It SustainableStock Portfolio Allocation Guidance for Volatile Markets - beatles.ru
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Gain the edge with real-time market data - Jammu Links News
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Stock Selection With High Accuracy - Newser
Does Mersana Therapeutics Inc. stock perform well during market downturnsExponential return rates - Jammu Links News
What are the latest earnings results for Mersana Therapeutics Inc.Invest confidently with professional guidance - Jammu Links News
How does Mersana Therapeutics Inc. generate profit in a changing economyRapidly expanding wealth - Jammu Links News
When is Mersana Therapeutics Inc. stock expected to show significant growthCapitalize on strong market momentum - Jammu Links News
How does Mersana Therapeutics Inc. compare to its industry peersGet timely alerts on top-performing stocks - Jammu Links News
Why is Mersana Therapeutics Inc. stock attracting strong analyst attentionRapid market gains - Jammu Links News
How volatile is Mersana Therapeutics Inc. stock compared to the marketIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Mersana Therapeutics Inc. stockRetirement Planning Insights For 2025 - Jammu Links News
How strong is Mersana Therapeutics Inc. company’s balance sheetStock Strategy Insights For Fast Growth - Jammu Links News
How Mersana Therapeutics Inc. stock performs during market volatilityShort Term Alpha Signals Review - beatles.ru
Full technical analysis of Mersana Therapeutics Inc. stockPortfolio Positioning Strategy With Timing - Newser
Will Mersana Therapeutics Inc. benefit from macro trendsGrowth Based Investment Plan Guidance Highlighted - metal.it
Published on: 2025-07-30 03:04:39 - metal.it
Published on: 2025-07-29 23:14:19 - metal.it
Will Mersana Therapeutics Inc. stock split in the near futureBreakout Stocks Insights To Watch Now - Jammu Links News
Mersana Therapeutics Inc. Sees Spike in Bullish Option FlowStable Entry High Return Opportunities in Focus - beatles.ru
Is Mersana Therapeutics Inc. a Top Dividend Stock to Watch in 2025Watchlist for Low Risk High Return Stocks Updated - metal.it
Top Risks to Consider Before Buying Mersana Therapeutics Inc. Stock Oversold Reversal Picks with Buy Zone - metal.it
What is Mersana Therapeutics Inc. company’s growth strategyUnmatched market performance - jammulinksnews.com
MRSN Trading Halted Due to Pending News - GuruFocus
What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Insider Monkey
Mersana Therapeutics To Carry Out 1-for-25 Reverse Stock Split On July 28th, 2025 - 富途牛牛
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):